Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmacielo Ltd V.PCLO

Alternate Symbol(s):  PCLOF

PharmaCielo Ltd. is a Canada-based global company with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis products to large channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Company’s all-natural cannabis into standardized, medicinal-grade dried cannabis flower, cannabis oil extracts and cannabis related products sold in bulk to pharmaceutical companies and medicinal cannabis distributors globally. In Colombia, PharmaCielo Colombia is a fully licensed cultivator, producer, and distributor of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis extracts. Ubiquo is a knowledge management and medical consultation system that aims to create access to healthcare for Colombians.


TSXV:PCLO - Post by User

Post by Betteryear2on May 01, 2023 10:03pm
262 Views
Post# 35424182

PharmaCielo Financial Results for the Fourth Quarter

PharmaCielo Financial Results for the Fourth Quarter
  • During 2022, PharmaCielo made shipments to 23 clients in 9 countries, with continued growth expected for 2023.
  • The Company's measured investments in revenue-generating sales channels resulted in revenues of $5.3 million in 2022, almost three-times more than the $1.9 million reported in 2021.
  • Consistent progress on streamlining the business, to move toward profitability - 2022 SG&A expenses represent a 40% reduction vs. 2021, and were 65% lower compared to 2020.
  • PharmaCielo's previously announced non-brokered private placement of debenture units will generate $6 million in additional capital through the end of Q3 2023.

All figures in Canadian dollars ($) unless otherwise specified

Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 1, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the fourth quarter and year ended December 31, 2022.


PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2022 (newsfilecorp.com)

<< Previous
Bullboard Posts
Next >>